{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:36:40Z","timestamp":1791434200303,"version":"4.3.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The pilot implementation of the RTSS\/AS01\n                      <jats:sub>E<\/jats:sub>\n                      (RTS,S) malaria vaccine in Ghana, Kenya, and Malawi marked a significant step in the fight against malaria. Given the scale of the rollout, which far exceeded the controlled environment of clinical trials, establishing a robust pharmacovigilance (PV) system to monitor rare but potentially serious adverse events following immunization (AEFIs) was a critical component of the program\u2019s design.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>\n                      In collaboration with technical partners, national health authorities monitored the safety of the RTS,S\/AS01\n                      <jats:sub>E<\/jats:sub>\n                      vaccine through strengthened existing routine pharmacovigilance systems and strategies in the three participating countries. Causality assessment of serious AEFIs by national expert advisory committees did not reveal any new safety concerns associated with the RTS,S\/AS01\n                      <jats:sub>E<\/jats:sub>\n                      vaccine or confirm the safety signals observed in the Phase 3 clinical trials. The PV efforts successfully supported the safe rollout of the vaccine, contributing to substantial public health benefits in these endemic regions. Challenges encountered included underreporting of AEFIs, delays in data submission and in investigating serious AEFIs, and poor report quality despite targeted investments to strengthen the systems.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and recommendations<\/jats:title>\n                    <jats:p>The pilot program highlighted PV challenges in resource-limited settings and provided useful insights for future vaccine rollouts. The lessons learned from these challenges emphasize the importance of sustained investment, particularly for AEFI investigations, and the need for innovations to improve health worker reporting. Research is needed to identify effective strategies for increasing reporting. Key recommendations include training and capacity building, resource allocation, surveillance and reporting, raising and maintaining public awareness, and collaboration and information sharing to ensure sustained PV efforts and robust safety surveillance in similar contexts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-026-05889-x","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T09:28:11Z","timestamp":1775294891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety monitoring of the RTS,S\/AS01E malaria vaccine: experiences and lessons from routine pharmacovigilance in Ghana, Kenya, and Malawi"],"prefix":"10.1186","volume":"25","author":[{"given":"Adela","family":"Ashie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Mandale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson","family":"Ndalama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delese","family":"Darko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Seaneke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric K.","family":"Boateng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sabblah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abena","family":"Asamoa-Amoakohene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwame","family":"Amponsa-Achiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naziru T.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Jalang\u2019o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Nkansah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Adu-Boahen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Siyoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Toroitich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christabel","family":"Khaemba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Nambwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujeet","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafiq N. A.","family":"Okine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alambo K.","family":"Mssusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"5889_CR1","doi-asserted-by":"publisher","DOI":"10.1211\/PJ.2015.20069061","author":"European Medicines Agency","year":"2015","unstructured":"European Medicines Agency. The first malaria vaccine received a positive scientific opinion from the EMA. Pharm J. 2015. https:\/\/doi.org\/10.1211\/PJ.2015.20069061.","journal-title":"Pharm J"},{"key":"5889_CR2","unstructured":"European Medicines Agency. Article 58 application. [cited 13 Nov 2024]. Available: https:\/\/www.ema.europa.eu\/en\/glossary-terms\/article-58-application."},{"key":"5889_CR3","unstructured":"World Health Organization. Malaria vaccine: WHO position paper - March 2022. Wkly Epidemiol Rec. 2022;97: 60\u201378. Available: https:\/\/www.who.int\/publications\/i\/item\/who-wer9709-61-80."},{"key":"5889_CR4","unstructured":"World Health Organization. Historic launch of malaria vaccine pilots in Africa - WHO - Regional Office for Africa. 2017. Available: http:\/\/www.afro.who.int\/news\/historic-launch-malaria-vaccine-pilots-africa."},{"key":"5889_CR5","unstructured":"World Health Organization. Malaria vaccine implementation programme. World Heal Organ. 2023 [cited 22 Aug 2024]. Available: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/malaria-vaccine-implementation-programme."},{"key":"5889_CR6","unstructured":"The Malaria Vaccine Pilot Evaluation. An evaluation of the cluster-randomised pilot implementation of RTS,S\/AS01 through routine health systems in moderate to high malaria transmission settings in sub-Saharan Africa: a postauthorization observational study. In: ClinicalTrials.gov [Internet]. 22 Apr 2020 [cited 18 Feb 2024] p. NCT03806465. Available: https:\/\/cdn.clinicaltrials.gov\/largedocs\/65\/NCT03806465\/Prot_ICF_000.pdf."},{"key":"5889_CR7","unstructured":"World Health Organization. Report of the WHO Global Advisory Committee Meeting on Vaccine Safety (GACVS) Meeting, 1\u20133 December 2020. Weekly Epidemiological Record. 2021. pp. 13\u201320. Available: https:\/\/www.who.int\/publications\/i\/item\/who-wer9603-13-20."},{"key":"5889_CR8","unstructured":"African Vaccine Regulatory Forum (AVAREF) | WHO | Regional Office for Africa. Available: https:\/\/www.afro.who.int\/health-topics\/immunization\/avaref."},{"key":"5889_CR9","doi-asserted-by":"crossref","unstructured":"Schellenberg D, Hamel M, Njuguna P, Furrer E, Praet N, Balakrishnan M R, et al. Assessing safety in the RTS,S\/AS01 malaria vaccine implementation programme: an overview and comparison of methods. D. Schellenberg, pers. comm. Accessed 24 February 2026.","DOI":"10.1186\/s12936-026-05887-z"},{"key":"5889_CR10","unstructured":"Government of Ghana. Public Health Act, 2015 (Act 851). Available: https:\/\/www.moh.gov.gh\/wp-content\/uploads\/2016\/02\/Public-Health-Act-851.pdf."},{"key":"5889_CR11","doi-asserted-by":"publisher","DOI":"10.1596\/40382","author":"H Wang","year":"2023","unstructured":"Wang H, Darko DM, Figueras Sune A, Marquez PV, Kumwenda J. Ghana\u2019s Pharmacovigilance Experience: From Vertical Program Activity to Nationwide System. Ghana\u2019s Pharmacovigil Exp From Vert Progr Act to Nationwide Syst. 2023. https:\/\/doi.org\/10.1596\/40382.","journal-title":"Ghana\u2019s Pharmacovigil Exp From Vert Progr Act to Nationwide Syst"},{"key":"5889_CR12","unstructured":"ICH Official web site\u202f: ICH. In: E2B(R3) Individual Case Safety Report (ICSR) Specification and Related Files [Internet]. 2023 [cited 23 Oct 2024]. Available: https:\/\/ich.org\/page\/e2br3-individual-case-safety-report-icsr-specification-and-related-files."},{"key":"5889_CR13","unstructured":"World Health Organization. Programme for International Drug Monitoring. [cited 13 Nov 2024]. Available: https:\/\/www.who.int\/teams\/regulation-prequalification\/regulation-and-safety\/pharmacovigilance\/networks\/pidm."},{"key":"5889_CR14","unstructured":"Med Safety App \u2013 WEB-RADR. [cited 23 Oct 2024]. Available: https:\/\/web-radr.eu\/mobile-apps\/med-safety\/."},{"key":"5889_CR15","unstructured":"PvERS: the Pharmacovigilance Electronic Reporting System: About. [cited 23 Oct 2024]. Available: https:\/\/pv.pharmacyboardkenya.org\/pages\/about."},{"key":"5889_CR16","unstructured":"Strengthening drug safety monitoring through innovation in Malawi. [cited 23 Oct 2024]. Available: https:\/\/tdr.who.int\/newsroom\/news\/item\/10-06-2022-strengthening-drug-safety-monitoring-through-innovation-in-malawi."},{"key":"5889_CR17","unstructured":"Malawi Pharmacy and Medicines Regulatory Authority. Malawi Pharmacovigilance Guidelines for healthcare professionals."},{"key":"5889_CR18","unstructured":"World Health Organization. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification second edition, 2019 update. 2019. Available: https:\/\/www.who.int\/publications\/i\/item\/9789241516990."},{"key":"5889_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjph-2023-000077","volume":"1","author":"NA Ansah","year":"2023","unstructured":"Ansah NA, Weibel D, Oladokun ST, Duah E, Ansah P, Oduro A, et al. Documenting capacity and existing gaps in reporting adverse events following immunisation in Northern Ghana: a quantitative cross-sectional survey of healthcare workers. BMJ Public Health. 2023;1:e000077. https:\/\/doi.org\/10.1136\/bmjph-2023-000077.","journal-title":"BMJ Public Health"},{"key":"5889_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40264-019-00898-z","volume":"43","author":"A Barry","year":"2020","unstructured":"Barry A, Olsson S, Minzi O, Bienvenu E, Makonnen E, Kamuhabwa A, et al. Comparative assessment of the national pharmacovigilance systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania. Drug Saf. 2020;43:339\u201350. https:\/\/doi.org\/10.1007\/s40264-019-00898-z.","journal-title":"Drug Saf"},{"key":"5889_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3745298","author":"CW Masika","year":"2016","unstructured":"Masika CW, Atieli H, Were T. Knowledge, perceptions, and practice of nurses on surveillance of adverse events following childhood immunization in Nairobi, Kenya. Biomed Res Int. 2016. https:\/\/doi.org\/10.1155\/2016\/3745298.","journal-title":"Biomed Res Int"},{"key":"5889_CR22","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2021.40.81.25910","author":"OO Malande","year":"2021","unstructured":"Malande OO, Munube D, Afaayo RN, Chemweno C, Nzoka M, Kipsang J, et al. Adverse events following immunization reporting and impact on immunization services in informal settlements in nairobi, kenya: A prospective mixed-methods study. Pan Afr Med J. 2021. https:\/\/doi.org\/10.11604\/pamj.2021.40.81.25910.","journal-title":"Pan Afr Med J"},{"key":"5889_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijans.2023.100639","author":"E Moyo","year":"2023","unstructured":"Moyo E, Moyo P, Mangoya D, Imran M, Dzinamarira T. Adverse drug reaction reporting by healthcare providers in sub-Saharan Africa: a scoping review of the challenges faced and the strategies to address the challenges. Int J Africa Nurs Sci. 2023. https:\/\/doi.org\/10.1016\/j.ijans.2023.100639.","journal-title":"Int J Africa Nurs Sci."},{"key":"5889_CR24","doi-asserted-by":"publisher","first-page":"S459","DOI":"10.1093\/cid\/civ599","volume":"61","author":"FVK Diomand\u00e9","year":"2015","unstructured":"Diomand\u00e9 FVK, Yam\u00e9ogo TM, Vannice KS, Preziosi MP, Viviani S, Ouandaogo CR, et al. Lessons learned from enhancing vaccine pharmacovigilance activities during PsA-TT introduction in African Countries, 2010-2013. Clin Infect Dis. 2015;61:S459\u201366. https:\/\/doi.org\/10.1093\/cid\/civ599.","journal-title":"Clin Infect Dis"},{"key":"5889_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4178\/epih.e2023054","volume":"45","author":"Y Noh","year":"2023","unstructured":"Noh Y, Ko HY, Kim JH, Yoon D, Choe YJ, Choe SA, et al. Barriers to COVID-19 vaccine surveillance: the issue of under-reporting adverse events. Epidemiol Health. 2023;45:1\u20137. https:\/\/doi.org\/10.4178\/epih.e2023054.","journal-title":"Epidemiol Health"},{"key":"5889_CR26","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.15585\/mmwr.mm7249a2","volume":"72","author":"EF Blau","year":"2023","unstructured":"Blau EF, Balakrishnan MR, Sk\u00f6ld H, Santhana Gopala Krishnan RS, Lundquist P, Pal S, et al. Progress in Immunization Safety Monitoring\u2014Worldwide, 2020\u20132022. MMWR Morb Mortal Wkly Rep. 2023;72:1321\u20136. https:\/\/doi.org\/10.15585\/mmwr.mm7249a2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"5889_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264697","author":"EB Laryea","year":"2022","unstructured":"Laryea EB, Frimpong JA, Noora CL, Tengey J, Bandoh D, Sabblah G, et al. Evaluation of the adverse events following immunization surveillance system, Ghana, 2019. PLoS ONE. 2022. https:\/\/doi.org\/10.1371\/journal.pone.0264697.","journal-title":"PLoS ONE"},{"key":"5889_CR28","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.vaccine.2019.11.050","volume":"38","author":"JF Gidudu","year":"2020","unstructured":"Gidudu JF, Shaum A, Dodoo A, Bosomprah S, Bonsu G, Amponsa-Achiano K, et al. Barriers to healthcare workers reporting adverse events following immunization in four regions of Ghana. Vaccine. 2020;38:1009\u201314. https:\/\/doi.org\/10.1016\/j.vaccine.2019.11.050.","journal-title":"Vaccine"},{"key":"5889_CR29","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1016\/j.vaccine.2019.09.109","volume":"38","author":"NE MacDonald","year":"2020","unstructured":"MacDonald NE, Guichard S, Arora N, Menning L, Wilhelm E. Lessons on causality assessment and communications from the 2019 South-East Asia Regional (SEAR) workshop on inter-country expert review of selected Adverse Events Following Immunization (AEFI) cases. Vaccine. 2020;38:4924\u201332. https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.109.","journal-title":"Vaccine"},{"key":"5889_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13867-6","author":"JU Stegmann","year":"2022","unstructured":"Stegmann JU, Jusot V, Menang O, Gardiner G, Vesce S, Volpe S, et al. Challenges and lessons learned from four years of planning and implementing pharmacovigilance enhancement in sub-Saharan Africa. BMC Public Health. 2022. https:\/\/doi.org\/10.1186\/s12889-022-13867-6.","journal-title":"BMC Public Health"},{"key":"5889_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277197","author":"RA Aborigo","year":"2022","unstructured":"Aborigo RA, Welaga P, Oduro A, Shaum A, Opare J, Dodoo A, et al. Optimising reporting of adverse events following immunisation by healthcare workers in Ghana: a qualitative study in four regions. PLoS ONE. 2022. https:\/\/doi.org\/10.1371\/journal.pone.0277197.","journal-title":"PLoS ONE"},{"key":"5889_CR32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/bcp.15193","volume":"89","author":"R Kiguba","year":"2023","unstructured":"Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low- and middle-income countries: a review with particular focus on Africa. Br J Clin Pharmacol. 2023;89:491\u2013509. https:\/\/doi.org\/10.1111\/bcp.15193.","journal-title":"Br J Clin Pharmacol"},{"key":"5889_CR33","unstructured":"World Health Organization. Immunization Safety Surveillance: Guidelines for immunization programme managers on surveillance of adverse events following immunization. 2015. Available: https:\/\/iris.who.int\/bitstream\/handle\/10665\/208262\/9789290617457_eng.pdf"},{"key":"5889_CR34","doi-asserted-by":"publisher","unstructured":"ASSAF. Root Causes of Low Vaccination Coverage and Under-Immunisation in Sub-Saharan Africa Report. Pretoria; 2021. https:\/\/doi.org\/10.17159\/assaf.2019\/0068","DOI":"10.17159\/assaf.2019\/0068"},{"key":"5889_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2020.106335","author":"VD Tsu","year":"2021","unstructured":"Tsu VD, LaMontagne DS, Atuhebwe P, Bloem PN, Ndiaye C. National implementation of HPV vaccination programs in low-resource countries: lessons, challenges, and future prospects. Prev Med (Baltim). 2021. https:\/\/doi.org\/10.1016\/j.ypmed.2020.106335.","journal-title":"Prev Med (Baltim)"},{"key":"5889_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-071079","author":"O Menang","year":"2023","unstructured":"Menang O, Kuemmerle A, Maigetter K, Burri C. Strategies and interventions to strengthen pharmacovigilance systems in low-income and middle-income countries: a scoping review. BMJ Open. 2023. https:\/\/doi.org\/10.1136\/bmjopen-2022-071079.","journal-title":"BMJ Open"},{"key":"5889_CR37","doi-asserted-by":"publisher","first-page":"7560","DOI":"10.1016\/j.vaccine.2019.09.082","volume":"37","author":"ME Koike","year":"2019","unstructured":"Koike ME, Gatt\u00e1s VL, Lucchesi MBB, Moura de Oliveira MM, Vanni T, Thom\u00e9 BdaC, et al. Pharmacovigilance capacity strengthening for WHO prequalification: the case of the trivalent influenza vaccine manufactured by Instituto Butantan. Vaccine. 2019;37:7560\u20135. https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.082.","journal-title":"Vaccine"},{"key":"5889_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1142\/S0218339014400051","volume":"22","author":"A Sharma","year":"2014","unstructured":"Sharma A, Misra AK. Modeling the impact of awareness created by media campaigns on vaccination coverage in a variable population. J Biol Syst. 2014;22:249\u201370. https:\/\/doi.org\/10.1142\/S0218339014400051.","journal-title":"J Biol Syst"},{"key":"5889_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038565","volume":"103","author":"DB Olawade","year":"2024","unstructured":"Olawade DB, Wada OZ, Ezeagu CN, Aderinto N, Balogun MA, Asaolu FT, et al. Malaria vaccination in Africa a mini-review of challenges and opportunities. Medicine. 2024;103:e38565. https:\/\/doi.org\/10.1097\/MD.0000000000038565.","journal-title":"Medicine"},{"key":"5889_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/ph17060807","author":"KVS Hodel","year":"2024","unstructured":"Hodel KVS, Fiuza BSD, Concei\u00e7\u00e3o RS, Aleluia ACM, Pitanga TN, Fonseca LMdosS, et al. Pharmacovigilance in vaccines: importance, main aspects, perspectives, and challenges\u2014a narrative review. Pharmaceuticals Basel. 2024. https:\/\/doi.org\/10.3390\/ph17060807.","journal-title":"Pharmaceuticals Basel"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-05889-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05889-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05889-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:40:30Z","timestamp":1778049630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12936-026-05889-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5889"],"URL":"https:\/\/doi.org\/10.1186\/s12936-026-05889-x","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"197"}}